Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
In furtherance of our intimation dated
June 24, 2022, and pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015, this is to inform you about the conclusion of the patent litigation brought by Indivior Inc. ("Indivior
Inc.") and Indivior UK Limited, ("Indivior UK," and together with Indivior Inc., "Indivior") and
Aquestive Therapeutics, Inc. ("Aquestive") relating to the Company's generic buprenorphine and naloxone sublingual
film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, a therapeutic equivalent generic version of Suboxone sublingual
film in U.S.A. On June 28, 2022 the U.S. Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant
to a joint stipulation of dismissal filed by the parties. The stipulation of dismissal was filed pursuant to a settlement agreement
that the Company entered into with Indivior and Aquestive. The settlement and dismissal resolves all claims between the parties,
including Indivior's and Aquestive's claims for patent infringement as well as the Company's antitrust counterclaim
This is for your information.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary & Compliance Officer |
| CC: | New York Stock Exchange Inc. (Stock Code :RDY) |
| NSE IFSC Ltd. |